INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2018

In obese, insulin-resistant men, 12 weeks of nicotinamide riboside supplementation was safe but did not improve insulin sensitivity or glucose metabolism.

Forty sedentary, obese men aged 40-70 years were randomized to receive 12 weeks of nicotinamide riboside (NR, 1000 mg twice daily) or placebo. NR supplementation did not improve insulin sensitivity, endogenous glucose production, glucose disposal, or glucose oxidation. Furthermore, NR had no effect on resting energy expenditure, lipolysis, lipid oxidation, or body composition. No serious adverse events occurred and safety blood tests remained normal.

Study type
Randomized, placebo-controlled, double-blind parallel trial
Who was studied
40 healthy, sedentary obese men (BMI > 30 kg/m2, age 40-70 y)
What was measured
Insulin sensitivity, substrate metabolism, resting energy expenditure, body composition, and safety

THE PAPER

A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.

Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, Stødkilde-Jørgensen H, Møller N, Brenner C, Treebak JT, Jessen N. Am J Clin Nutr, 2018.

PubMed 29992272 ↗DOI 10.1093/ajcn/nqy132 ↗

Diabetes & blood sugarNutrients & adequacyWeight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.